News
AKLI
1.570
+18.05%
0.240
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
TipRanks · 03/11 21:45
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/07 21:31
reports Q4 results
Seeking Alpha · 03/07 21:21
Akili's Q4 Non-GAAP Loss Widens, Revenue Declines; Shares Down After Hours
Akili's Q4 Non-GAAP Loss Widens, Revenue Declines; Shares Down After Hours
MT Newswires · 03/07 17:23
Earnings Scheduled For March 7, 2023
Benzinga · 03/07 13:37
GENE, RSLS and TMC are among pre market gainers
Seeking Alpha · 02/03 13:18
Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update
Seeking Alpha · 01/30 05:27
Morgan Stanley Sticks to Its Hold Rating for Akili (AKLI)
TipRanks · 01/25 16:27
Where Akili Stands With Analysts
Benzinga · 01/25 15:00
--Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating
--Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating
MT Newswires · 01/25 10:33
Akili Cuts Workforce by 30% to Reduce Costs
Akili Cuts Workforce by 30% to Reduce Costs
MT Newswires · 01/12 13:29
BRIEF-Akili Inc Says Company's Workforce Will Be Reduced By About 30%
Reuters · 01/12 13:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/05 21:30
KALA, KC and CTMX are among pre market gainers
Seeking Alpha · 01/05 13:28
BRIEF-Akili Inc Announces Results From Pivotal Trial Of Endeavorrx In Adolescents With ADHD
Reuters · 01/05 12:14
Akili Reports Positive Topline Results From Study of EndeavorRx to Treat Adolescents With ADHD; Shares Rise Pre-Bell
Akili Reports Positive Topline Results From Study of EndeavorRx to Treat Adolescents With ADHD; Shares Rise Pre-Bell
MT Newswires · 01/05 09:32
Morgan Stanley Initiates Coverage On This Digital Therapeutics Stock With Attractive View
Benzinga · 12/29/2022 19:44
Akili Needs 'Strong Launch' in EndeavorRx to Gain Investor Confidence, Morgan Stanley Says
Akili Needs 'Strong Launch' in EndeavorRx to Gain Investor Confidence, Morgan Stanley Says
MT Newswires · 12/28/2022 15:04
Expert Ratings for Akili
Benzinga · 12/28/2022 15:00
More
Webull provides a variety of real-time AKLI stock news. You can receive the latest news about Akili through multiple platforms. This information may help you make smarter investment decisions.
About AKLI
Akili, Inc. (Akili), formerly Social Capital Suvretta Holdings Corp. I, is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company develops digital therapeutics that combine science and technology to address cognitive impairments in patients. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Akili’s products are delivered through captivating action video game experiences.